Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income turns negative
Q1 FY2026 operating income was -$3.13M, compared with $1.29M a year earlier. Trailing-twelve-month operating income was -$7.21M.
Context
- Operating income amounted to 6.3% of revenue in FY2025, down 10.7 pp from a year earlier.
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 1 analysts of -$7.64M (-173.5%) for the fiscal year ending Dec 2026, a slowdown from the +56.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.13M-128.2% QoQ
- Last fiscal yearDec 2025
- -$2.79M+56.6% YoY
- LTMMar 2026
- -$7.21M-120.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -342.2% | -166.7% | +175.5 pp |
| 1 year | +56.6% | -173.5% | -230.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (2.79M) USD
- Year-over-year change
- +56.6%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.79M) | +56.6% |
| FY2024 | 2024-12-31 | (6.43M) | +32.7% |
| FY2023 | 2023-12-31 | (9.55M) | -67.5% |
| FY2022 | 2022-12-31 | (5.7M) | +25.7% |
| FY2021 | 2021-12-31 | (7.68M) | — |
Operating Income vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's LTM Mar 2026 operating income of -$7.21M is the 2nd highest of the 4 companies compared; the peer median is -$16.61M.
- Its year-over-year change of -120.5% is the lowest of 4, against a peer median of -22.7%.
- Operating income amounts to 17.2% of revenue for CPIX, versus a peer median of 234.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$7.09M | -22.7% | — | 238.4% | |
| LTM Mar 2026 | -$7.21M | -120.5% | — | 17.2% | |
| LTM Mar 2026 | -$16.61M | +21.9% | — | — | |
| LTM Dec 2025 | -$61.31M | -59.8% | — | 230.9% | |
| Peer median (excluding CPIX) | -$16.61M | -22.7% | — | 234.7% | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 35.99M | 42.01M | 39.55M | 37.87M | 44.52M |
| Cost of Revenue | 8.81M | 9.12M | 6.07M | 6.59M | 6.67M |
| Gross Profit | 27.17M | 32.89M | 33.49M | 31.28M | 37.85M |
| Gross Margin | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% |
| Research & Development | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M |
| Selling, General & Admin | 24.8M | 26.84M | 29.1M | 28.15M | 31.05M |
| Operating Expenses | 34.85M | 38.6M | 43.04M | 37.71M | 40.65M |
| Depreciation & Amortization | 4.61M | 5.33M | 8.1M | 6.04M | 5.29M |
| EBITDA | (857.83K) | 332.92K | 2.49M | 182.42K | 2.96M |
| EBITDA Margin | -2.4% | 0.8% | 6.3% | 0.5% | 6.6% |
| Operating Income | (7.68M) | (5.7M) | (9.55M) | (6.43M) | (2.79M) |
| Operating Margin | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% |
| Interest Income | 26.08K | 98.41K | 286.85K | 334.44K | 476.75K |
| Interest Expense | 98.03K | 586K | 667.86K | 605.51K | 495.99K |
| Other Income / Expenses | 2.12M | 123.74K | 3.27M | (33.98K) | (32.46K) |
| Income Before Tax | (5.56M) | (5.58M) | (6.28M) | (6.47M) | (2.82M) |
| Pre-Tax Margin | -15.5% | -13.3% | -15.9% | -17.1% | -6.3% |
| Income Tax Expense | 34.89K | 68.85K | 45.77K | (22.67K) | 40.26K |
| Net Income | (3.51M) | (5.57M) | (6.28M) | (6.48M) | (2.84M) |
| Net Margin | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% |
| EPS (Basic) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| EPS (Diluted) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
| Weighted Avg Shares | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
| Weighted Avg Shares (Diluted) | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.